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The basis for selective death of specific neuronal
populations in neurodegenerative diseases remains
unclear. Parkinson’s disease (PD) is a synucleinop-
athy characterized by a preferential loss of dopami-
nergic neurons in the substantia nigra (SN), whereas
neurons of the ventral tegmental area (VTA) are
spared. Using intracellular patch electrochemistry
to directly measure cytosolic dopamine (DAcyt) in
cultured midbrain neurons, we confirm that elevated
DAcyt and its metabolites are neurotoxic and that
genetic and pharmacological interventions that
decrease DAcyt provide neuroprotection. L-DOPA
increased DAcyt in SN neurons to levels 2- to 3-fold
higher than in VTA neurons, a response dependent
on dihydropyridine-sensitive Ca2+ channels, resulting
in greater susceptibility of SN neurons to L-DOPA-
induced neurotoxicity. DAcyt was not altered by
a-synucleindeletion, althoughdopaminergicneurons
lacking a-synuclein were resistant to L-DOPA-
induced cell death. Thus, an interaction between
Ca2+,DAcyt, anda-synucleinmayunderlie thesuscep-
tibility of SN neurons in PD, suggesting multiple ther-
apeutic targets.
INTRODUCTION
Parkinson’s disease (PD) is characterized by aggregation of
alpha-synuclein (a-syn) into Lewy bodies and Lewy neurites,
and a progressive loss of specific neuronal populations. In
particular, ventral midbrain (VM) dopamine (DA) neurons of the
substantia nigra (SN) preferentially degenerate in PD, while
neighboring ventral tegmental area (VTA) DA neurons are rela-
tively spared (Dauer and Przedborski, 2003). A role of a-syn in
PD pathogenesis is demonstrated by cases of familial PD that218 Neuron 62, 218–229, April 30, 2009 ª2009 Elsevier Inc.result from mutations or overexpression of a-syn, as well as by
the observation that SN neurons in mice with a-syn deletion
are protected against the parkinsonian neurotoxins MPTP and
6-OHDA (Alvarez-Fischer et al., 2008; Dauer et al., 2002). Several
hypotheses may explain a-syn-mediated cytotoxicity, including
the formation of toxic aggregates that disrupt membrane (Con-
way et al., 2001), a blockade of lysosomal protein degradation
(Martinez-Vicente et al., 2008), and mitochondrial dysfunction
(Ved et al., 2005). It has also been recently suggested that high
Ca2+ levels due to Cav1.3 channel-dependent pacemaking
activity (Nedergaard et al., 1993) may contribute to SN suscepti-
bility, as VTA neurons use Na+ channels for pacemaking (Chan
et al., 2007). Accordingly, Cav1.3 antagonists block SN cell
death in MPTP and other neurotoxin models (Chan et al.,
2007). The reason for the preferential death of SN DA neurons
is, however, unclear, as both a-syn and Cav1.3 channels are
expressed throughout the CNS in neurons that are not lost in
PD (Clayton and George, 1998; Rajadhyaksha et al., 2004;
Striessnig et al., 2006).
A long-standing hypothesis of neurodegeneration in PD postu-
lates that the buildup of cytosolic DA (DAcyt) with associated oxy-
radical stress and its possible interaction with a-syn and other
PD-related proteins underlie neurotoxicity (Caudle et al., 2008;
Chen et al., 2008; Edwards, 1993; Pardo et al., 1995; Sulzer
and Zecca, 2000). A role for DAcyt in the selectivity of cell death
in PD, however, has never been directly studied due to a lack of
means to measure DAcyt. Here we use a new electrochemical
approach to measure DAcyt in neurons following various pharma-
cological and genetic interventions. We report that ‘‘multiple
hits’’ consisting of high cytoplasmic Ca2+, elevated DAcyt, and
a-syn expression are required to evoke selective death of dopa-
minergic neurons from SN and show that interference with any of
these three factors rescues the neurons.
RESULTS
We previously introduced intracellular patch electrochemistry
(IPE) to study the regulation of cytosolic catecholamine
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Dopamine, Calcium, a-Synuclein, and Neurotoxicityhomeostasis in cultured primary murine adrenal chromaffin cells
(Mosharov et al., 2003) and the PC12 cell line (Mosharov et al.,
2006). To extend IPE measurements to DA neurons, we em-
ployed VM cultures from mice that express green fluorescent
protein under the control of the tyrosine hydroxylase (TH)
promoter (TH-GFP; see Figure S1 available online) (Sawamoto
et al., 2001). Immunolabeling of fixed 2-week-old cultures of
VM neurons for TH showed that approximately 97% of GFP+
cells were TH+ (185 of 191 cells).
Dependence of DAcyt on Extracellular L-DOPA
IPE measurements in cyclic voltammetric (CV) mode that detects
DA preferentially over other intracellular metabolites (including L-
3,4-dihydroxyphenylalanine [L-DOPA] and dihydroxyphenylace-
tic acid [DOPAC]) revealed that DAcyt in untreated GFP
+ neurons
was below the detection limits of the technique (<0.1 mM). This
was similar to DAcyt levels in PC12 cells (Mosharov et al., 2006),
but differed from the 10–20 mM cytosolic catecholamine concen-
trations found in untreated chromaffin cells (Mosharov et al.,
2003). We previously demonstrated that 1 hr pretreatment with
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B Figure 1. L-DOPA Metabolic Consumption
by VM Neurons
(A) Time dependence of DAcyt following cell treat-
ment with two L-DOPA concentrations. *p < 0.05
versus 1 hr time point by one-way ANOVA (n =
9–52 cells in different groups).
(B) Dependence of DAcyt on extracellular L-DOPA
in mouse neurons treated with the drug for 1 hr
(n = 10–24 cells). Solid line indicates the fit of
the data points using the equation [DAcyt] =
DAmax*[L-DOPA]/(K0.5 + [L-DOPA]).
(C) HPLC-EC measurements of the total intracel-
lular DA and DOPAC in rat VM (n = 9 dishes) and
cortical (n = 3) neuronal cultures exposed to 100
or 500 mM L-DOPA for 1 hr; N.D., not detected.
*p < 0.05 versus untreated cultures.
(D) HPLC measurements of intracellular L-DOPA
contents in rat VM cultures pretreated with the
AADC inhibitor benserazide (2 mM; 1 hr) and then
treated with 50, 100, or 500 mM L-DOPA for 1 hr
(n = 3–8 dishes). Solid line indicates the fit of the
data points using the equation [L-DOPAintracell] =
DOPAmax*[L-DOPAextracell]/(K0.5 + [L-DOPAextracell]).
(E) Dependence of the rate of L-DOPA auto-oxida-
tion on the initial L-DOPA concentration deter-
mined by HPLC-EC in a cell-free system. The
half-life was calculated from the incline (k) of the
linear fit of the data points as t1/2 = Ln(2)/k.
(F) Time dependence of extracellular L-DOPA
concentration modeled using kinetic constants
from (E). The dashed line indicates K0.5 from (B).
Data in (A)–(D) are means ± SEM.
100 mM L-DOPA produces a 2- to 3-fold
increase of cytosolic catecholamine
concentration in chromaffin cells (Mosh-
arov et al., 2003). The same dose of
L-DOPA increased DAcyt in GFP
+ neurons
to 17.4 ± 1.7 mM (mean ± SEM; n = 74
cells).
To determine the kinetics of DAcyt changes after L-DOPA
treatment, we performed IPE at 1, 8, 15, and 24 hr after
L-DOPA addition to the media. After 1 hr of 100 mM L-DOPA
exposure, DA in the cytosol reached a steady-state level that
was maintained for 8 hr, followed by a decline to control levels
over the succeeding 24 hr of drug treatment (Figure 1A). Interest-
ingly, 500 mM L-DOPA increased DAcyt to the same maximum
level, but the elevated steady state was maintained longer, and
24 hr after L-DOPA treatment, DAcyt was still higher than in
untreated cells. To study the dependence of DAcyt on extracel-
lular L-DOPA, neuronal cultures were treated with a range of
L-DOPA concentrations for 1 hr at 37C, followed by IPE
measurements in the presence of the same L-DOPA concentra-
tions in the bath and in the pipette solutions within the following
30 min at room temperature. The drug response curve was
hyperbolic (Figure 1B) with an apparent K0.5 of10 mM L-DOPA.
As the steady-state DA concentration in neuronal cytosol is
regulated by multiple enzymes and transporters, we attempted
to determine which metabolic step limited DAcyt accumulation in
L-DOPA-treated cells. High-performance liquid chromatographyNeuron 62, 218–229, April 30, 2009 ª2009 Elsevier Inc. 219
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total intracellular DA (the majority of which represents vesicular
DA; Chien et al., 1990; Mosharov et al., 2003) and DOPAC
contents showed that these metabolites were elevated to the
same degree in neurons exposed to 100 and 500 mM L-DOPA
(Figure 1C), indicating that there was no difference in the rates
of DA oxidation by monoamine oxidase A (MAO) and vesicular
uptake by vesicular monoamine transporter 2 (VMAT2). To estab-
lish whether L-DOPA transport into the cell or its conversion to
DA by aromatic L-amino acid decarboxylase (AADC) limited the
L-DOPA metabolic consumption, we measured total intracellular
L-DOPA levels in VM cultures after 1 hr treatment with 100 and
500 mM L-DOPA concentrations in the presence of the AADC
inhibitor benserazide to block DA synthesis (Figure 1D). The initial
rate of L-DOPA accumulation in the cells was not saturated under
these conditions, consistent with previously published data (Sam-
paio-Maia et al., 2001) on the kinetics of L-DOPA uptake by cell
lines derived from astrocytes and neurons (Km = 50–100 mM).
Overall, these data suggest that the activity of AADC limits the
steady-state DAcyt concentration following L-DOPA treatment.
The data in Figure 1C also provide information about the rate
of L-DOPA turnover by the cells. The combined rate of DA
and DOPAC synthesis during 1 hr of L-DOPA exposure was
40 fmol/mg of total protein. As each culture dish typically con-
tained 50100 mg of total protein, the rate of L-DOPA consump-
tion during 10 hr of incubation was 20–40 pmol per culture. This
rate, however, is too low to account for the decline in the DAcyt
observed after 10 hr of cell incubation with L-DOPA (Figure 1A),
as the total amount of available L-DOPA was >3 orders of magni-
tude higher (200 nmol in 2 ml of 100 mM solution). We therefore
examined the availability of extracellular L-DOPA, which is known
to auto-oxidize to DOPA-semiquinone and DOPA-quinone deriv-
atives (Sulzer and Zecca, 2000). HPLC-EC measurements of
L-DOPA concentration in cell-free media showed that the drug
disappeared with first-order kinetics and a half-life of 4.7 hr
(Figure 1E). This suggests that after 100 or 500 mM L-DOPA initial
doses, its concentration in the media would reach the K0.5 levels
in 16 or 26 hr, respectively (Figure 1F), which is in close agreement
with the kinetics of DAcyt changes, as a significant decrease in its
initial steady state was observed at approximately these time
points (Figure 1A). Together, these data allow us to predict the
time dependence of DAcyt changes based on the concentration
of L-DOPA added to the media and the initial increase in DAcyt
determined by IPE (see Discussion).
L-DOPA-Induced Neurotoxicity
We next investigated whether exposure to various L-DOPA
concentrations, and thereby different durations of sustained
elevated DAcyt, correlated with neurotoxicity. We identified an
exponential dependence of neurotoxicity on the extracellular
L-DOPA concentration (Figure 2A), whereas the time depen-
dence for cell survival in cultures treated with 250 mM L-DOPA
demonstrated that the number of TH+ neurons declined linearly
after drug exposure, reaching 50% of the control levels after
4 days, with no subsequent neuronal loss (Figure 2B). As
L-DOPA at this concentration is cleared within 22 hr, the data
indicate a lag between the end of L-DOPA/DA-mediated stress
and the completed course of the catechol-induced toxicity. For220 Neuron 62, 218–229, April 30, 2009 ª2009 Elsevier Inc.further experiments we exposed cultures to 250 mM L-DOPA,
which consistently produced 50% loss of VM dopaminergic
neurons 4 days following drug addition.
Extracellular DA released by neuronal activity did not seem to
play a significant role in the L-DOPA-induced cell death, as
neuronal viability was not affected by the Na+ channel blocker
tetrodotoxin (TTX; 1 mM), which inhibits stimulation-dependent
transmitter release (data not shown). To further determine which
pool of DA was responsible for the observed cell damage, we
employed postnatal cultures of cortical and striatal neurons,
which do not express TH, DAT, or VMAT. Following L-DOPA
treatment of cortical neurons, we detected small amounts of
DA measured by HPLC-EC (Figure 1C) and a substantial eleva-
tion of DAcyt measured by IPE (Figure 2C). This was accompanied
by >60% loss of cells immunoreactive to microtubule-associated
protein 2 (MAP2), which was used as a neuronal marker
(Figure 2D). L-DOPA neurotoxicity was NSD-1015 sensitive,
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Figure 2. L-DOPA-Induced Neurotoxicity in DA and Non-DA
Neurons
(A) The loss of TH+ neurons in mouse VM cultures treated with different L-DOPA
concentrations for 4 days. A similar decline in the number of VMAT2-positive
neurons was observed (data not shown). The average number and the density
of TH+ neurons in untreated cultures were 200–250 neurons/culture and
10–15 neurons/mm2, respectively. The solid line is the fit of the data with an
exponential decay function. *p < 0.001 versus age-matched controls by one-
way ANOVA.
(B) Time dependence of DA neuron survival in cultures treated with 250 mM
L-DOPA. **p < 0.001 versus untreated cells by two-way ANOVA (n = 3–4 dishes).
(C) DAcyt in mouse cortical (n = 59) and striatal (n = 21) neurons incubated with
100 mM L-DOPA for 1 hr.
(D) L-DOPA-induced toxicity in cortical and striatal neurons exposed to
250 mM for 4 days and immunostained for MAP2. *p < 0.01 versus untreated
cells by t test (n = 3–5 dishes).
Dotted lines and shadowed boxes in (A) and (D) represent mean ± SEM in
untreated cells.
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(data not shown). In contrast, almost no DAcyt was detected in
L-DOPA-treated striatal neurons, and they were spared following
L-DOPA challenge (Figures 2C and 2D). Together, our data
suggest DAcyt as the primary source of the L-DOPA-induced
neurotoxicity.
Pharmacological Manipulation of DAcyt
and Neurotoxicity
AADC, MAO, and VMAT Inhibitors
To study the contribution of individual metabolic pathways in the
maintenance of the DAcyt steady state and to determine whether
changes in DA level correlate with neurotoxicity, we performed
metabolite measurements and toxicity studies on L-DOPA-
treated neurons that were preincubated with specific inhibitors
of AADC, MAO, and VMAT. Inhibition of the DA-synthesizing
enzyme AADC with NSD-1015 (Figures 3A and 3B) or bensera-
zide (not shown) blocked L-DOPA-induced elevation of whole-
cell intracellular DA and DOPAC. Benserazide also inhibited
the buildup of DAcyt following L-DOPA treatment (Figure 3C),
consistent with the idea that the IPE oxidation signal comes
from DA synthesized by AADC in the cytosol (note that NSD-
1015 alters IPE sensitivity for DA, and therefore was not exam-
ined; see Experimental Procedures). Moreover, the blockade of
L-DOPA decarboxylation completely prevented drug-induced
cell death (Figure 3D), indicating that an L-DOPA metabolite,
but not L-DOPA itself, was responsible for the toxicity.
The contribution of DA catabolism was investigated by treat-
ing cells with pargyline, an inhibitor of MAO that almost
completely abolished DOPAC synthesis (Figure 3B). Pargyline
also produced a several-fold increase in both the total amount
of intracellular DA (Figure 3A) and DAcyt (Figure 3C) in L-DOPA-
treated neurons, which further correlated with a significantly
greater neuronal loss (Figure 3D).
The blockade of VMAT-mediated DA uptake into the vesicles
depletesvesicularcatecholaminestorage,asobservedbyareduc-
tion in the exocytotic quantal size (Colliver et al., 2000). Consis-
tently, pretreatment of VM neurons with reserpine decreased the
amount of total intracellular DA synthesized from L-DOPA by 2-
fold both with and without pargyline (Figure 3A). We observed,
however, no effectof reserpine,oranother VMAT inhibitor, tetrabe-
nazine (10 mM; data not shown), on either DAcyt or the number of
surviving dopaminergic neurons (Figures 3C and 3D).
Methamphetamine and Cocaine
The discrepancy between the reduction of the total DA in reser-
pine-treated neurons and the lack of the effect of VMAT inhibition
on DAcyt might be explained by the distribution of synaptic vesi-
cles between neuronal cell bodies and the neurites. If the
majority of vesicles filled with DA are located in synaptic termi-
nals far from the cell bodies, any transmitter redistributed from
them would be invisible to IPE (see Experimental Procedures).
To examine the effects of other DA-releasing drugs on somatic
DA concentration, we exposed L-DOPA-treated neurons to meth-
amphetamine (METH), which disrupts the vesicular proton
gradient and redistributes DA from synaptic vesicles to the cytosol
(Sulzer et al., 2005). In contrast to the increased cytosolic cate-
cholamine levels observed in chromaffin cells acutely treated
with METH (Mosharov et al., 2003), neurons exposed to 50 mMMETHshoweddecreased DAcyt (Figure3E); 5mM METHproduced
the same decrease of DAcyt (38% of untreated cells; p < 0.005 by
t test). METH-mediated reduction of DAcyt was blocked by the DA
uptake transporter (DAT) inhibitor cocaine, suggesting that the
effect was due to reverse transport through DAT (Sulzer et al.,
2005). METH-mediated decrease of DAcyt and its blockade by
cocaine were also observed in L-DOPA-treated cells in the pres-
ence of pargyline (data not shown). Note that DAcyt in L-DOPA-
treated neurons was unaffected by DAT inhibitors cocaine
(Figure 3E) or nomifensine (5 mM; data not shown), supporting
the idea that reverse transport is not induced by the elevated DAcyt
alone, but requires additional METH-mediated effects on DAT
(Kahlig et al., 2005).
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Figure 3. Effect of Pharmacological Inhibitors on DAcyt and Neuro-
toxicity
(A and B) HPLC-EC measurements of total intracellular DA (A) and DOPAC (B)
in rat VM neuronal cultures pretreated for 1 hr with 500 mM NSD-1015, 2 mM
reserpine (Res), or 10 mM pargyline (PGL) and then treated with 100 mM
L-DOPA for 1 hr (n = 6–10 dishes). N.D., not detected.
(C) DAcyt in mouse VM neurons under the same treatments as above except for
2 mM benserazide (Bsrz) to block AADC (n = 22–81 cells).
(D) The effect of NSD-1015, benserazide, reserpine, and pargyline on the
survival of mouse TH+ neurons treated with 250 mM L-DOPA for 4 days (n =
6–20 dishes).
(E) DAcyt concentration in TH-GFP neurons pretreated with 10 mM cocaine for
15 min, then exposed to 100 mM L-DOPA for 1 hr, and then treated with 50 mM
METH for 15–30 min (n = 19–46 cells).
(F) Cell survival of mouse TH+ neurons pretreated with METH and cocaine as in
(E) and exposed to 250 mM L-DOPA for 4 days (n = 3–8 dishes).
*p < 0.05 versus cells treated with L-DOPA only by one-way ANOVA. Dotted lines
and shadowed boxes in (D) and (F) represent mean ± SEM in untreated cells.Neuron 62, 218–229, April 30, 2009 ª2009 Elsevier Inc. 221
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bodies from L-DOPA toxicity (Figure 3F), despite the consider-
able neurite loss that occurs in METH-treated cultured DA
neurons (Cubells et al., 1994; Larsen et al., 2002). When applied
for 4 days without L-DOPA, neither METH or cocaine nor the
combination of the two drugs had a significant effect on the
number of surviving neurons (data not shown).
Genetic Manipulation of DAcyt and Neurotoxicity
VMAT2 Overexpression
We previously developed a recombinant adenovirus that overex-
presses VMAT2 (rVMAT2), resulting in reduced neuronal neuro-
melanin content and enhanced quantal size, and which increased
the number of evoked quantal neurotransmitter release events
from the terminals of cultured VM dopaminergic neurons (Pothos
et al., 2000; Sulzer and Pothos, 2000). To investigate whether
enhanced vesicular uptake may decrease DAcyt and rescue
neurons from L-DOPA-induced toxicity, we employed an adeno-
viral construct that resulted in overexpression of the recombinant
VMAT2 in 80%–90% of both dopaminergic and nondopaminer-
gic cells (Figure S2).
VMAT2 overexpression significantly decreased DAcyt in
L-DOPA-treated GFP+ VM neurons (from 17.4 ± 1.7 mM, n = 74
neurons to 3.1 ± 0.8 mM, n = 28; Figure 4A), but had no effects
on GFP neurons from the same culture (2.4 ± 0.8 mM, n = 33
versus 2.3 ± 1.9 mM, n = 7). GFP+ neurons in cultures treated
with a virus that did not contain rVMAT2 displayed the same DAcyt
levels after L-DOPA treatment as control cells (data not shown).
Consistent with the kinetics of L-DOPA metabolic consumption
(Figure 1), rVMAT2 lowered DAcyt to the same extent in cells
treated with 100 and 500 mM L-DOPA (Figure 4A). Moreover,
infection with rVMAT2 effectively protected TH+ neurons from
the L-DOPA-mediated neurotoxicity (Figure 4B). It should be
noted, however, that these data also suggest that somatic vesi-
cles or other organelles that do not normally sequester substan-
tial levels of DA can do so after transporter overexpression, as
has been demonstrated for noncatecholaminergic AtT-20 cells
(Pothos et al., 2000) and hippocampal neurons (Li et al., 2005).
a-Synuclein Knockout
To investigate the role of a-syn in mediating DAcyt neurotoxicity,
we generated a-syn-deficient mice that express eGFP in dopa-
minergic neurons (see Experimental Procedures). Whereas VM
neurons from a-syn/ and a-syn+/ mice were more resistant
to L-DOPA-induced stress than neurons from their wild-type
littermates (Figure 4C), IPE measurements indicated no differ-
ence in the DAcyt concentration between the three groups
(Figure 4D). These data suggest that the pathogenic effect of
a-syn is downstream of DA synthesis (see Discussion), and
that the presence of both elevated DAcyt and a-syn is required
for L-DOPA-induced neurotoxicity.
DAcyt in SN and VTA Neurons
To address the question of differential susceptibility of neurons
from different brain regions, we prepared cultures that were en-
riched with cells from either SN or VTA, as previously published
(Burke et al., 1998). Immunolabeling for calbindin, a protein that
is expressed at higher levels in VTA than in SN (Thompson et al.,
2005), showed that in mixed VM cultures 50% of TH+ neurons222 Neuron 62, 218–229, April 30, 2009 ª2009 Elsevier Inc.were also calbindin+, whereas the proportion of TH+/calbindin+
cells was 85% in VTA cultures and 25% in SN cultures
(Figures 5A and 5B).
IPE measurements showed that L-DOPA-treated SN neurons
displayed 2- to 3-fold higher DAcyt than VTA neurons
(Figure 5C). This difference in DAcyt translated into a significantly
higher susceptibility of SN neurons to L-DOPA-induced toxicity,
whereas VTA neurons were almost completely protected
(Figure 5D). The resistance of VTA neurons to L-DOPA challenge
was also seen in mixed VM cultures, where after 4 days of 250 mM
L-DOPA the percentage of TH+/calbindin+ neurons increased
from 52% to 88% (p < 0.05 by c2 test).
Relationship between Cytoplasmic Ca2+ and DAcyt
The regulation of intracellular Ca2+ differs significantly between
SN and VTA neurons (Gerfen et al., 1985; Surmeier, 2007;
Thompson et al., 2005). Thus, to search for the mechanism that
governs the difference in DAcyt between the two neuronal
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Figure 4. Effect of VMAT2 Overexpression and a-Syn Knockout on
DAcyt and Toxicity
(A) DAcyt in sister cultures of mouse TH
+ neurons treated with L-DOPA for 1 hr;
cells were either untransfected or were transfected with rVMAT2 or empty
vector (not shown) 1 day before the application of L-DOPA. *p < 0.01 versus
cells treated with L-DOPA only by one-way ANOVA (n = 15–28 cells).
(B) Neuroprotection of TH+ neurons in rat VM cultures infected with rVMAT2 or
empty vector and exposed to varying concentrations of L-DOPA on day 1 and
assessed for survival on day 7. *p < 0.05 versus empty vector by two-way
ANOVA.
(C) Reduced sensitivity of TH+ neurons from a-syn-deficient mice to L-DOPA-
induced neurotoxicity. Neurons from a-syn wild-type, heterozygous, and
knockout littermate mice were treated with indicated L-DOPA concentrations
for 4 days. *p < 0.05 and **p < 0.001 versus the wild-type by two-way ANOVA
with Bonferroni post hoc test (n = 10–29 dishes).
(D) Comparison of DAcyt levels in neurons from a-syn knockout, heterozygous,
and wild-type mice treated with 100 mM L-DOPA for 1 hr (n = 20–49 cells).
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Figure 5. Sensitivity of SN and VTA DA
Neurons to L-DOPA Challenge
(A) Representative images of VM neuronal cultures
double stained for TH and calbindin. The scale bar
represents 20 mm.
(B) Relative number of calbindin+ cells within the
population of TH+ neurons.
(C) Cytosolic DA concentrations in VM, SN, and
VTA TH+ neurons treated with 100 mM L-DOPA
for 1 hr. The representative experiment shown
was repeated five times with 9–16 cells in each
group in each experiment. p < 0.01 versus VM (*)
or versus VM and SN (**) by one-way ANOVA.
(D) L-DOPA-induced neurotoxicity in cultures
treated with 250 mM L-DOPA for 4 days. Dotted
lines and shadowed boxes represent mean ±
SEM in untreated cells. p < 0.01 versus untreated
neurons of the same group (*) or versus L-DOPA-
treated neurons of all other groups (**) by one-
way ANOVA (n = 10–15 dishes).populations, we investigated whether intracellular Ca2+ had an
effect on L-DOPA-induced DAcyt accumulation.
Cell pretreatment with the voltage-gated calcium channel
blocker CdCl2 or buffering cytoplasmic Ca
2+ with the membrane-
permeable chelator BAPTA-AM both significantly decreased
DAcyt in dopaminergic neurons from SN and VTA (Figure 6A).
This suggests that the regulatory mechanism that links cyto-
plasmic Ca2+ and DAcyt exists in both cell populations, and that
the difference between SN and VTA neurons might be in the
steady-state Ca2+ level. This would be consistent with SN
neurons relying on dihydropyridine-sensitive L-type Cav1.3
channels for autonomous pacemaking, in contrast to VTA
neurons that use Na+ channels for pacemaking. Immunostaining
of VM cultures for the a1D subunit of the L-type Ca2+ channels,
which is specifically present in the Cav1.3 channels, showed
that it expressed in both calbindin+ and calbindin DA neurons
(Figure S3), consistent with previous reports (Rajadhyaksha
et al., 2004; Striessnig et al., 2006). The Cav1.2/Cav1.3 blockers
nimodipine (Figure 6A) and nitrendipine (not shown), however,
had no effect on DAcyt in L-DOPA exposed VTA neurons, but
decreased DAcyt in SN neurons to the levels found in VTA neurons
(Figure S4). VM cultures treated with nimodipine were far more
resistant to L-DOPA-induced neurodegeneration (Figure 6B).
Pretreatment of SN neurons for 1 hr with the HCN channel antag-
onist ZD7288 (50 mM) or TTX (1 mM) had no significant effect on
DAcyt reached after L-DOPA treatment (data not shown).
To determine which enzyme or transporter is responsible
for Ca2+-induced upregulation of DA homeostasis, we first
compared DAcyt in SN and VTA neurons treated with pargyline
and reserpine. DAcyt was increased by the same percentile in
both types of neurons (Figure 6C), suggesting that MAO and
VMAT2 activities did not underlie the difference between DAcyt
handling by SN and VTA neurons and were not the regulatory
targets. Next, DAcyt in SN and VTA neuronal cultures was unaf-
fected by the presence of the DAT blocker cocaine (data notshown). Finally, the uptake of L-DOPA in VM cultures pretreated
with BAPTA-AM and benserazide was monitored by HPLC-EC
and IPE in the amperometric detection mode, which in contrast
to CV produces similar oxidative currents for DA and L-DOPA
(Mosharov et al., 2003). Measurements by both methods
demonstrated that L-DOPA uptake was unaffected by Ca2+ buff-
ering (Figures 6D and 6E). Overall, our data suggest that MAO,
VMAT, DAT, and the L-amino acid plasma transporter were not
responsible for the difference in DAcyt observed between SN
and VTA neurons. Thus, it appears that the activity of AADC
may provide the Ca2+-sensitive metabolic step that leads to
higher DAcyt levels in SN neurons.
DISCUSSION
Efforts over the past decade have identified genes that cause
familial instances of several neurodegenerative disorders,
including Parkinson’s disease. The steps underlying the degen-
eration of the specific neuronal populations associated with
these diseases, however, have proven elusive. Here we show
that selective death of SN dopaminergic neurons responsible
for the definitive motor deficits in PD can result from a combina-
tion of multiple hits resulting from the activity of the L-type Ca2+
channels that create high cytoplasmic Ca2+ levels, an upregula-
tion of DAcyt synthesis by Ca
2+, and the presence of a-synuclein.
Dependence of Neurotoxicity on DAcyt
A series of studies have suggested that dysregulation of DAcyt
maintenance underlies neuropathology in PD, but characteriza-
tion of DAcyt and its relationship to neurotoxicity has not been
possible due to a lack of means to measure DAcyt. We have
adapted the recently introduced technique of IPE to characterize
DA homeostasis in neuronal cytosol.
Our results confirm a relationship between high levels of DAcyt
and neurotoxicity. A variety of pharmacological and geneticNeuron 62, 218–229, April 30, 2009 ª2009 Elsevier Inc. 223
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was mediated by the cytosolic pool of DA, whereas other poten-
tial sources of cellular stress, including extracellular DA and
L-DOPA, played limited roles under our experimental conditions.
To compare the data from different experiments, we examined
the dependence of cell survival on the integral of cell exposure
to elevated DA levels (DAcyt dose; Figure 7A; Figure S5). The rela-
tionship was close to linear, with doses above 100–200 mM$hr
A
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Figure 6. Regulation of DAcyt by Cytoplasmic Ca
2+
(A) DAcyt in SN and VTA neurons pretreated with 30 mM CdCl2, 10 or 100 mM
BAPTA-AM, or 10 mM nimodipine (Nmdp) for 1 hr, and then exposed to
100 mM L-DOPA for 1 hr. Data are presented as relative changes compared
to SN and VTA neurons treated with L-DOPA only. *p < 0.05 versus L-DOPA
only by one-way ANOVA (n = 11–52 cells).
(B) Protection of SN neurons from L-DOPA-induced neurotoxicity by the
L-type Ca2+ channel blocker nimodipine (10 mM; 1 hr pretreatment). *p < 0.05
versus L-DOPA only by one-way ANOVA (n = 3–23 dishes).
(C) DAcyt levels in SN and VTA neurons pretreated with 2 mM reserpine and
10 mM pargyline for 1 hr and then exposed to 100 mM L-DOPA for 1 hr. *p <
0.05 versus corresponding L-DOPA-only group by one-way ANOVA (n = 18–27
cells).
(D) Whole-cell L-DOPA concentration in VM cultures pretreated for 1 hr with
2 mM benserazide with and without 10 mM BAPTA-AM and then exposed to
100 mM L-DOPA for 1 hr (n = 4 dishes).
(E) Total cytosolic catechol concentrations (IPE in amperometric mode) in VM
neurons either untreated or treated as in (D) (n = 10 cells).224 Neuron 62, 218–229, April 30, 2009 ª2009 Elsevier Inc.causing significant neurotoxicity. This finding was consistent
over a wide variety of interventions that altered DAcyt in different
manners, including inhibition of L-DOPA conversion to DA,
VMAT2 blockade or overexpression, and treatment with METH
and cocaine. Cortical neurons were less resistant to L-DOPA
challenge than midbrain DA neurons, although there are no
reports of cell loss in the cortex of PD patients who received
L-DOPA for many years. Conversely, VM neurons treated with
the MAO inhibitor pargyline were significantly more resistant
to DAcyt-mediated toxicity (Figure 7A, asterisk). One possible
explanation for the lower than expected levels of cell death
observed in the presence of MAO blockade is a contribution of
DA catabolic products that arise via MAO activity, that is, H2O2
and dihydroxyphenylacetaldehyde (DOPAL), as has been
recently suggested (Burke et al., 2004; Eisenhofer et al., 2004).
Although additional studies are required to characterize other
factors that modulate susceptibility of neurons to stress, our
data support the exploration of central MAO inhibitors as treat-
ments for PD either as monotherapy at early stages of the
disease or in combination with L-DOPA in the advanced disease
stages (Chen et al., 2007; Hauser et al., 2008); in both cases,
MAO blockers would increase the availability of DAcyt for vesic-
ular sequestration while preventing the buildup of toxic DA
metabolites.
DAcyt Maintenance in Neuronal Somas
and Synaptic Terminals
Perhaps surprisingly, reserpine and METH, drugs that disrupt
vesicular DA sequestration, did not increase DAcyt, despite
the depletion of vesicular DA stores evident from HPLC-EC
measurements of the total intracellular DA (Figure 3; Larsen
et al., 2002). These results are, however, consistent with diffu-
sion calculations, indicating that IPE measures only DA in the
cell body (see Experimental Procedures), that is, the number
of DA storage vesicles in the soma might be insufficient to de-
tectably increase DAcyt following reserpine or METH. Although
some DA secretory organelles reside in or close to neuronal
cell bodies, as evident from somatodendritic vesicular DA
release from midbrain neurons (Jaffe et al., 1998; Rice et al.,
1997), emptying one synaptic vesicle containing 10,000 DA
molecules (Pothos et al., 1998) would increase DAcyt by only
0.01 mM (see Experimental Procedures), and 150–200 such
vesicles would need to be emptied to produce a 10% increase
over the 15–20 mM DAcyt observed in L-DOPA-treated cells.
In comparison, adrenal chromaffin cells, which lack neurites
and are filled with secretory vesicles that each contain
1,000,000 transmitter molecules (Wightman et al., 1991),
show increased cytosolic catechol concentrations following
reserpine or METH (Mosharov et al., 2003). Although IPE
cannot measure DAcyt in axonal terminals, it is possible that
a similarly large increase in DAcyt occurs in METH-treated
neuronal terminals and, if so, this may explain the unusual
pattern of METH-induced neurodegeneration in which neurites
but not cell bodies are damaged in vitro (Cubells et al., 1994;
Larsen et al., 2002), in animal models in vivo (Ricaurte et al.,
1982), and in imaging studies of METH abusers after prolonged
abstinence (Chang et al., 2007). Postmortem examination of
chronic METH users reveals a more severe DA axonal loss in
Neuron
Dopamine, Calcium, a-Synuclein, and Neurotoxicitythe caudate than in the putamen, presumably explaining the
lack of parkinsonian symptoms in METH abusers (Moszczynska
et al., 2004).
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Figure 7. DAcyt Dose and Neurotoxicity
(A) Dependence of cell survival under L-DOPA-induced stress on the DAcyt
dose in mouse neurons. DAcyt dose was estimated as [DAcyt]$TExposure =
[DAcyt]$Ln([L-DOPA]/K0.5)/k, where [DAcyt] is the concentration of cytosolic
DA in cells treated with a saturating level (>50 mM) of L-DOPA for 1 hr,
[L-DOPA] is the initial drug concentration, and K0.5 = 9.7 mM and k = 0.15 hr
1
are the kinetic constants derived from Figures 1B and 1E, respectively.
TExposure therefore approximates the time during which extracellular L-DOPA
remained higher than K0.5 (Figure 1F). The data points are (from left to right):
filled circles: VM cultures treated with 25, 100, 250, 500, and 1000 mM
L-DOPA alone; open circles: VM neurons treated with 250 mM L-DOPA in
the presence of benserazide, METH, reserpine, PGL, and PGL + reserpine;
diamonds: VTA and SN neurons; and triangles: striatal and cortical neurons
treated with 250 mM L-DOPA. Dotted lines and shadowed boxes represent
mean ± SEM in untreated cells. The solid line is the linear fit of all data points,
excluding striatal and cortical neurons, and two data points indicated by an
asterisk. Treatments to the right of this line are neuroprotective, as the same
level of cell death is achieved with higher DAcyt doses; treatments to the left
of the line are more susceptible to DAcyt stress.
(B) Multi-hit model of PD pathogenesis. Neurotoxicity is a result of multiple
factors, including the presence of a-syn, elevation of cytoplasmic Ca2+, and
the buildup of DAcyt and its metabolites. Nonexclusive toxic steps may result
from (1) mechanisms that require direct interaction between DA or its metab-
olites with a-syn, such as DA-modified stabilization of a-syn protofibrils or inhi-
bition of chaperone-mediated autophagy, or (2) cumulative damage from
multiple independent sources. Decreasing the levels of any of the three players
provides neuroprotection.Upregulation of DA Homeostasis by Ca2+ Explains
Higher Vulnerability of SN Neurons to L-DOPA-Induced
Stress
We found that DAcyt reached in L-DOPA-treated dopaminergic
neurons directly correlated with intracellular Ca2+, as lower DAcyt
levels were found in SN and VTA neurons following voltage-
gated calcium channel blockade by CdCl2 or cytoplasmic Ca
2+
buffering by BAPTA-AM. Conversely, significantly higher DAcyt
was reached in SN than in VTA neurons, consistent with the
pacemaking activity of dihydropyridine-sensitive Cav1.3 chan-
nels in SN but not VTA neurons. Notably, although dihydropyri-
dines nimodipine and nitrendipine had no effect on DAcyt
concentration in VTA neurons, they decreased DAcyt in SN
neurons to the levels in the VTA, and provided neuroprotection
from L-DOPA-induced cell death.
The target of Ca2+-dependent upregulation of DA homeostasis
appears to be the conversion of L-DOPA to DA by AADC.
Although regulation of AADC activity via protein kinase A- and
C-mediated phosphorylation has been reported (Duchemin
et al., 2000; Young et al., 1998), these mechanisms require further
characterization, as Cav1.3 channels are also regulated by these
second-messenger pathways (Baroudi et al., 2006; Rajadhyak-
sha and Kosofsky, 2005). It should also be noted that Ca2+-
dependent phosphorylation of TH (Dunkley et al., 2004) is likely
to play a role in the absence of exogenously added L-DOPA.
A Multiple-Hit Hypothesis of SN Neurodegeneration
in PD
Multiple genes have been identified to cause familial PD, but the
disease may require multiple steps, such as an initial insult
together with an insufficient stress response (Abou-Sleiman
et al., 2006; Conway et al., 2001; LaVoie et al., 2005; Martinez-
Vicente et al., 2008; Moore et al., 2005; Sang et al., 2007; Sulzer,
2007), which may explain why known genetic and environmental
factors do not straightforwardly account for idiopathic PD. The
interaction between high DAcyt and a-syn may provide one of
the multiple-hit mechanisms. Due to the presence of a-syn in
Lewy bodies and the role of a-syn mutations or gene multiplica-
tion in some forms of familial PD, it is widely believed that this
protein plays a central role in the degeneration of VM DA
neurons. Consistent with previous reports that dopaminergic
neurons in a-syn deficient mice show reduced susceptibility to
neurotoxins (Alvarez-Fischer et al., 2008; Dauer et al., 2002),
we found that a-syn deletion makes VM neurons resistant to
L-DOPA-induced toxicity. By contrast, neuronal DAcyt was unaf-
fected by the absence of a-syn (Figure 4D), similar to cytosolic
catecholamine levels in chromaffin cells from a-syn null animals
(Mosharov et al., 2006). These data are consistent with a toxic
mechanism downstream of DA synthesis that may involve stabi-
lization of toxic a-syn protofibrils by DA, inhibition of chaperone-
mediated autophagy by DA-modified a-syn, or a cumulative
stress from various sources, which, in addition to DAcyt, Ca
2+,
and a-syn, may include mitochondrial and proteasomal dysfunc-
tion and inflammatory responses (Figure 7B) (Burke et al., 2008;
Conway et al., 2001; Dauer and Przedborski, 2003; Gao et al.,
2008; Martinez-Vicente et al., 2008; Ved et al., 2005). Addition-
ally, although normal expression levels of mouse wild-type
a-syn do not seem to affect DAcyt concentration, a-syn mutationNeuron 62, 218–229, April 30, 2009 ª2009 Elsevier Inc. 225
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2002; Mosharov et al., 2006) that would further exacerbate
neurotoxicity.
It is striking that L-DOPA doses that produced neurotoxicity in
this study also induce the synthesis of neuromelanin (Sulzer
et al., 2000), an autophagosome containing oxidized dopamine
products (Sulzer et al., 2008). Moreover, VMAT2 overexpression,
which as we show here decreased DAcyt and abolished L-DOPA-
induced neuronal death, has also been demonstrated to inhibit
neuromelanin synthesis (Sulzer et al., 2000). Together, these
data support the idea that neuromelanin synthesis is a stress
response and that the presence of neuromelanin in human SN
and its accumulation over time are indicative of an ongoing DAcyt
damage even in normal non-PD human brain. Conversely, dopa-
minergic neurons in the VTA, which are spared in PD, produce
minimal neuromelanin over a lifetime (Hirsch et al., 1988; Liang
et al., 2004; Zecca et al., 2001).
Whereas DA neurons are comparatively resistant to DAcyt
toxicity, it remains unclear whether neurotoxic DAcyt levels are
reached in humans, particularly during treatment of PD patients
with L-DOPA. Although L-DOPA therapy is linked to increased
levels of the products of peroxynitrite-mediated oxidative stress
in cerebrospinal fluid (CSF) (Isobe et al., 2006) and a more rapid
decline in striatal dopamine transporter over the course of
L-DOPA therapy, there is no increase in the rate of symptomatic
progression in PD patients with L-DOPA (Fahn, 2005). Moreover,
whereas recent reports demonstrate L-DOPA-induced neuro-
toxicity in rodents (Chen et al., 2008; Jeon et al., 2007), other
in vivo studies found L-DOPA to be benign or even neuroprotec-
tive (reviewed by Olanow et al., 2004). Important factors may
include the ability of L-DOPA-induced mild oxidative stress to
activate glutathione synthesis (Han et al., 1996; Mena et al.,
1997) and induce macroautophagy (Sulzer et al., 2008), and
a likely protective action of L-DOPA therapy on the striatopallidal
pathway (Day et al., 2006). Normal L-DOPA concentration in the
CSF is only5 nM (Tohgi et al., 1997) and increases to300 nM
in L-DOPA-treated patients (Tohgi et al., 1995), which is likely
within a range that cellular stress response pathways can
handle. It should be emphasized that the meaning of our findings
is not that L-DOPA is neurotoxic to humans, as it is artificially
used as a tool to enhance DA: genuine PD does not result from
L-DOPA exposure, but may result following chronically elevated
DAcyt and the presence of other genetic and environmental hits.
The newly identified relationship between high Ca2+ and DAcyt
may underlie the selective vulnerability of dopaminergic neurons
in SN and locus coeruleus, a group of noradrenergic neurons
that also rely on Ca2+ channel pacemaking (Williams et al.,
1984). If so, various strategies could be employed to prevent
neuronal death in PD, including an inhibition of Cav1.3 channel
activity (Surmeier, 2007) or blocking the deleterious effects of
DA-protein interactions (Martinez-Vicente et al., 2008). By
contrast, symptomatic treatment of PD relies on therapies that
enhance synaptic vesicle sequestration of DA, thereby reconsti-
tuting the dopaminergic tone in the striatum. As discussed above,
our data may indicate advantages to using central MAO inhibitors
as PD drugs. Likewise, as we show here, VMAT2 overexpression
enhances exocytotic DA release while decreasing DAcyt. Because
VMAT2 overexpression not only promotes DA neurotransmission226 Neuron 62, 218–229, April 30, 2009 ª2009 Elsevier Inc.in a manner similar to L-DOPA but also confers neuroprotection,
controlled VMAT2 overexpression may provide a therapeutic
intervention for PD, either alone or in combination with L-DOPA
or MAO blockers.
EXPERIMENTAL PROCEDURES
Mouse Strains
For neurotoxicity and IPE experiments, neurons from C57/Bl6 mice or from
transgenic mice that express green fluorescent protein (TH-GFP+/) under
the control of the rat tyrosine hydroxylase (TH) promoter (Sawamoto et al.,
2001) were used. a-synuclein null mice that express eGFP under the control
of TH promoter were generated in two steps. TH-GFP+/ mice were crossed
with a-syn/ mice (strain B6;129X1-Sncatm1Rosl/J from Jackson Labs; origi-
nally from Abeliovich et al., 2000). Next, the resulting TH-GFP+//a-syn+/
mice were crossed with each other and genotyped for the presence of
both eGFP and a-syn to obtain TH-GFP+//a-syn+/, TH-GFP+//a-syn/,
and TH-GFP+//a-syn+/+ littermates. For HPLC measurements, cells from
Sprague-Dawley rats were used. Animals were used in accordance with the
National Institutes of Health guidelines for the use of live animals, and the animal
protocol was approved by the Institutional Animal Care and Use Committee of
Columbia University.
Primary Neuronal Cultures
Ventral midbrain (VM), cortical, or striatal neurons from postnatal day 0–2 mice
or rats were dissected, dissociated, and plated on a monolayer of cortical
astrocytes at the plating density of 100,000 cells/cm2, as previously
described (Burke et al., 1998; Rayport et al., 1992). Mouse neurons were
cultured on glass poly-D-lysine-coated coverslips attached to 0.8 cm2 wells
cut into 50 mm dishes. Rat neurons were cultured on 35 mm tissue culture
dishes (9.6 cm2).
We previously reported (Mena et al., 1997) that lower levels of L-DOPA
provided a short-lasting enhancement of dopaminergic neuron survival due
to neuroprotective antioxidant responses to L-DOPA-induced oxidative stress.
We have since demonstrated that glial-derived neurotrophic factor (GDNF) is
selectively neuroprotective for postnatally derived dopaminergic neurons,
providing markedly enhanced survival (Burke et al., 1998), and now routinely
include this component in the culture medium. As shown in the present study,
L-DOPA is not neuroprotective in the presence of GDNF (Figure 2A), presum-
ably because the neuroprotective response has been occluded, allowing the
toxic response to be revealed.
Experiments were conducted 6–10 days postplating; all treatments were per-
formed at 37C. Pseudo-3D images of cultured TH-GFP neurons (Figure S1)
were obtained with a two-photon microscope (Zeiss Axioskop2 FS MOT
upright microscope, LSM 510 Coherent two-photon setup; Carl Zeiss Micro-
Imaging, Thornwood, NY, USA), using 850 nm excitation and 525 nm emission
wavelengths. Z sections were taken at 1 mm increments. Other images were
acquired on a conventional fluorescence microscopy setup (Zeiss Axiovert
100 microscope) equipped with a Zeiss AxioCam MRm camera and FITC and
rhodamine filter sets (Chroma, Rockingham, VT, USA).
Adenoviral Vector Construction and Transfection of Neurons
with rVMAT2
A hemagglutinin (HA) -tagged VMAT2 cDNA was first subcloned into the
shuttle vector pTet-EF, then coinfected with donor virus DNA (45) into
HEK293 cells expressing Cre recombinase, and the resultant VMAT2-HA-
harboring adenovirus was purified and stored as previously described at
8000 pfu/ml (Krantz et al., 1997). Primary rat VM cultures were incubated
with 1 ml of rVMAT2 diluted in 100 ml of media for 5 hr and then 2 ml of media
was added to each dish;45 alone was used as a negative (empty virus) control.
Transfection efficiency was 80%–90% for both dopaminergic and GABAergic
neuronal types (Figure S2).
Immunocytochemistry and Western Blots
Immunostaining of 4% paraformaldehyde-fixed cultures was performed using
mouse or rabbit anti-TH (1:1000; Chemicon, Temecula, CA, USA), rabbit
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St. Louis, MO, USA) antibodies, followed by secondary antibodies conjugated
with Alexa 488 or Alexa 594 (1:200; Molecular Probes, Eugene, OR, USA).
Polyclonal rabbit anti-VMAT2 antibody (1:200; Pel-Freez Biologicals, Rogers,
AR, USA) was used to detect endogenous and exogenous VMAT2 protein.
For immunodetection of HA-tagged rVMAT2, cultures were stained using
monoclonal anti-HA antibody (1:200; BabCO, Richmond, CA, USA) (Pothos
et al., 2000). Western immunoanalysis of VMAT2 protein was performed as
described (Krantz et al., 1997) with VMAT2 antibody (1:500; Chemicon), horse-
radish peroxidase-conjugated secondary antibody, and visualization by
enhanced chemiluminescence (Pierce Biotech, Rockford, IL, USA).
Neurotoxicity
Cells were preincubated with rVMAT2 for 1 day and with various DA metabo-
lism inhibitors for 1 hr before the application of L-DOPA, unless stated other-
wise. Following 1–7 days of incubation, neuronal cultures were fixed and
stained for TH (VM neurons) or MAP2 (cortical and striatal neurons). The total
numbers of immunoreactive neurons were then tallied and analyzed as previ-
ously described (Larsen et al., 2002). Alternatively, neuronal density was
assessed by counting the number of immunoreactive cells in 24 fields of
view at 2003 magnification (Plan-Neofluar 203 objective; 0.8 mm2 viewing
field) and taking the average as a representative for each dish. Although the
two methods yielded similar results, the second approach was more robust,
producing lower deviation within experimental groups. The counts were per-
formed by an observer blind to the experimental treatments.
High-Performance Liquid Chromatography with Electrochemical
Detection
Whole-cell DA, dihydroxyphenylacetic acid (DOPAC), and L-DOPA levels were
determined by HPLC-EC as previously described (Feigin et al., 2001; Larsen
et al., 2002). DA, DOPAC, and L-DOPA amounts were calculated from areas
under HPLC peaks using calibration curves and normalized to protein concen-
trations in each sample.
Intracellular Patch Electrochemistry
Measurements of cytosolic DA (DAcyt) concentrations in neurons were based
on protocols for PC12 cells and chromaffin cells (Mosharov et al., 2003,
2006). A polyethylene-coated 5 mm carbon fiber electrode (CFE) was placed
inside a glass patch pipette and used in cyclic voltammetric (CV) mode of
detection where voltage ramps from 450 mV holding potential to +800 mV
and back to 450 mV over 10 ms (scan rate of 250 mV/ms) were applied at
100 ms intervals. After achieving a seal between the cell and the patch pipette,
the plasma membrane was ruptured by suction and substances diffusing from
the cytosol into the pipette were observed as a slow wave of oxidation current.
As no difference was found between IPE signals using intracellular and extra-
cellular ionic compositions as the patch pipette saline (Mosharov et al., 2003),
the same saline was employed as the bath and the pipette solutions in the
present study. The saline contained (in mM): 118 NaCl, 2.5 KCl, 2 MgCl2,
2 CaCl2, 1 NaH2PO4, 10 glucose, 25 HEPES-NaOH (pH 7.4); the same concen-
trations of all drugs, including L-DOPA, were present in the bath and in the
patch pipette. After background current subtraction, the concentration of DA
at the pipette tip was calculated as previously described (Mosharov et al.,
2003). IPE sensitivity, estimated as the current 3-fold higher than the root
mean square of the noise on the subtraction voltammogram, was 100 nM
DA; the calibration curves were log-linear for up to at least 1 mM DA concen-
tration (Mosharov et al., 2003). The initial concentration of DAcyt was calculated
using neuronal cell-body volume, and the volume of the pipette tip was esti-
mated from photographs taken before each recording (Figure S1).
To investigate whether the electrode sensitivity for DA was affected by the
presence of compounds present in the recording media, we performed a series
of calibration measurements of 5 mM DA with and without the drugs (Table S1).
Based on these data, NSD-1015 cannot be used for IPE experiments because
it abolished the oxidation signal of DA.
Although CV voltammograms cannot differentiate between DA, L-DOPA, and
the product of DA catabolism, DOPAC, there are several reasons to suspect
that DA represented the majority of the cytosolic oxidation signal estimated
by IPE. First, the sensitivity of CV is 15- to 20-fold higher for DA moleculesthan for other catechols (Mosharov et al., 2003). Second, there were identical
concentrations of L-DOPA present in the patch pipette and extracellular saline
during the recordings; thus, any change in the oxidation signal after achieving
the whole-cell configuration could not be due to the influx of L-DOPA into the
patch pipette per se. Third, L-DOPA is rapidly converted to DA once in the
cytosol, and enhanced DA can be measured in these cultures within 90 s
(Pothos et al., 1998), whereas, as shown in Results, inhibition of AADC almost
completely abolished the oxidation signal from L-DOPA-treated cells. Finally,
neitherL-DOPA nor DOPAC are VMAT2substrates, arguingagainst a possibility
that the observed decrease in the cytosolic signal in neurons overexpressing
VMAT2 was due to nonspecific catechol uptake into the vesicles.
To estimate the contribution of neurotransmitter from neurites to the CV
oxidation signal, we calculated the time required for DA to diffuse into the cell
body and then into the patch pipette. The average neuronal soma diameter
and the distance from the cell to the CFE measured from photographs acquired
before the recordings were 17.3 ± 3.9 mm and 16.6 ± 3.9mm, respectively. Diffu-
sion time (t) was calculated as t = x2/2D, where x is the distance and D is the DA
diffusion coefficient, 2.7*106 cm2/s (Nicholson, 1999). It follows that DA from
the middle of the cell body (x = 25.3mm) would reach the CFE in 1.2 s, which was
close to the average time to oxidation peak maximum experimentally observed
in IPE recordings (1.4 ± 0.8 s, mean ± SEM, n = 34 neurons; Figure S1). In
contrast, it would take approximately ten times longer for DA to diffuse from
a varicosity positioned three cell-body diameters away (x = 77.1 m); this delay
would be longer still if the shape and diffusional barriers within the neurite
were taken into account. We conclude that the majority of DA measured by
IPE represents neurotransmitter that resided within the neuronal soma.
Possible Influence of Vesicular DA Cargo on the DAcyt
Measurements
If one synaptic vesicle releases all its content inside the neuronal soma, the
change in the DAcyt concentration will equal QN/NA/Vcell, where QN is vesicular
quantal size (10,000 molecules in L-DOPA-treated neuronal synaptic vesicles;
Pothoset al., 1998), NA is Avogadro’s Constant (6.023*10
23 molecules/mol), and
Vcell is the cell-soma volume (1.77 pl for a cell with a diameter of 15 mm). It
follows that emptying one vesicle would increase DAcyt by 10 nM, although
this value might be underestimated because the effective cytosolic volume is
smaller due to the presence of other organelles. In a similar scenario inside
a synaptic terminal (1 mm in diameter), DAcyt will be increased by >30 mM.
Statistical Analyses
Statistical analysis was performed in Prism 4 (GraphPad Software, La Jolla,
CA, USA), using one-way analysis of variance (ANOVA) followed by Tukey’s
post hoc test for comparisons across multiple groups or two-way ANOVA
with Bonferroni post test for the paired data.
SUPPLEMENTAL DATA
Supplemental data include five figures and a table and can be found with this
article online at http://www.neuron.org/supplemental/S0896-6273(09)00166-4.
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